The Prognostic Value of Serum Soluble Programmed Death 1 (sPD-1) and Programmed Death Ligand 1 (sPD-L1) in Esophageal Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis About Cohort Studies

IF 2.1 Q2 MEDICINE, GENERAL & INTERNAL Health Science Reports Pub Date : 2024-11-25 DOI:10.1002/hsr2.70178

Qiyao Yu, Jie Li, Wenjie Mao, Zheng Li, Xuan Li, Bin Li

{"title":"The Prognostic Value of Serum Soluble Programmed Death 1 (sPD-1) and Programmed Death Ligand 1 (sPD-L1) in Esophageal Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis About Cohort Studies","authors":"Qiyao Yu, Jie Li, Wenjie Mao, Zheng Li, Xuan Li, Bin Li","doi":"10.1002/hsr2.70178","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background and Aims</h3>\n \n <p>There are still no useful biomarkers for the prognosis of esophageal squamous cell carcinoma (ESCC). In the prognosis of some kinds of cancer, soluble programmed death 1 (sPD-1) and programmed death ligand 1 (sPD-L1) have demonstrated statistical significance, but the prognostic value of serum sPD-L1 and sPD-1 remains unclear in ESCC.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Here, a meta-analysis was performed to estimate the prognostic value of sPD-L1 and sPD-1 in ESCC. To obtain eligible studies, we searched mainstream databases (PubMed, Cochrane, Embase, Web of Science, Wanfang Data, and CNKI), and the survival data including hazard ratios (HR) and its 95% confidence intervals (95% CI) from included literature were extracted.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Six articles were included, including 645 patients with ESCC. The statistical result of this meta-analysis indicated that serum sPD-1 had no significant correlation with overall survival (OS) of patients with ESCC (<i>p</i> > 0.05). Patients with ESCC with high concentrations of serum sPD-L1 demonstrated a significantly poor prognosis (HR = 1.73, 95% CI: 1.42–2.11, <i>p</i> < 0.001).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Higher levels of serum sPD-L1 may predict poor OS in ESCC patients, which may be a promising and credible prognostic biomarker for esophageal cancer.</p>\n </section>\n </div>","PeriodicalId":36518,"journal":{"name":"Health Science Reports","volume":"7 11","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hsr2.70178","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Health Science Reports","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/hsr2.70178","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background and Aims

There are still no useful biomarkers for the prognosis of esophageal squamous cell carcinoma (ESCC). In the prognosis of some kinds of cancer, soluble programmed death 1 (sPD-1) and programmed death ligand 1 (sPD-L1) have demonstrated statistical significance, but the prognostic value of serum sPD-L1 and sPD-1 remains unclear in ESCC.

Methods

Here, a meta-analysis was performed to estimate the prognostic value of sPD-L1 and sPD-1 in ESCC. To obtain eligible studies, we searched mainstream databases (PubMed, Cochrane, Embase, Web of Science, Wanfang Data, and CNKI), and the survival data including hazard ratios (HR) and its 95% confidence intervals (95% CI) from included literature were extracted.

Results

Six articles were included, including 645 patients with ESCC. The statistical result of this meta-analysis indicated that serum sPD-1 had no significant correlation with overall survival (OS) of patients with ESCC (p > 0.05). Patients with ESCC with high concentrations of serum sPD-L1 demonstrated a significantly poor prognosis (HR = 1.73, 95% CI: 1.42–2.11, p < 0.001).

Conclusion

Higher levels of serum sPD-L1 may predict poor OS in ESCC patients, which may be a promising and credible prognostic biomarker for esophageal cancer.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

食管鳞状细胞癌血清可溶性程序性死亡 1 (sPD-1) 和程序性死亡配体 1 (sPD-L1) 的预后价值：关于队列研究的系统综述和荟萃分析

背景和目的目前尚无有效的生物标志物用于预测食管鳞状细胞癌（ESCC）的预后。在某些癌症的预后中，可溶性程序性死亡1（sPD-1）和程序性死亡配体1（sPD-L1）具有统计学意义，但血清sPD-L1和sPD-1在ESCC中的预后价值仍不明确。方法在此，我们进行了一项荟萃分析，以估计 sPD-L1 和 sPD-1 在 ESCC 中的预后价值。为了获得符合条件的研究，我们检索了主流数据库（PubMed、Cochrane、Embase、Web of Science、万方数据和 CNKI），并从纳入的文献中提取了包括危险比（HR）及其 95% 置信区间（95% CI）在内的生存数据。结果共纳入6篇文章，包括645名ESCC患者。荟萃分析的统计结果表明，血清sPD-1与ESCC患者的总生存率（OS）无显著相关性（p > 0.05）。血清 sPD-L1 浓度较高的 ESCC 患者预后明显较差（HR = 1.73，95% CI：1.42-2.11，p < 0.001）。结论血清sPD-L1水平较高可预测ESCC患者较差的OS，这可能是食管癌一种有希望的、可信的预后生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊